Vinnova   Report issue

Government Phase 2
Founded: Stockholm Sweden (2001)

Organization Overview

First Clinical Trial
2017
NCT03386552
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Vinnova